Phase2 study of bevacizumab with carboplatin–paclitaxel for non-small cell lung cancer with malignant pleural effusion

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Medical Oncology

• Publication date

  2013-08-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12032-013-0676-7PMID 23925664
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion

  2013cited by this paper
• Markers of response for the antiangiogenic agent bevacizumab.

  2013cited by this paper
• VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.

  2012cited by this paper
• Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab

  2012cited by this paper
• Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.

  2012cited by this paper
• Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer

  2011cited by this paper
• 804 ORAL Evaluation of Plasma VEGFA as a Potential Predictive Pan-tumour Biomarker for Bevacizumab

  2011cited by this paper
• Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

  2009cited by this paper
• Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials

  2009cited by this paper
• Monoclonal anti‐vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusion

  2009cited by this paper
• Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515.

  2007cited by this paper
• Bevacizumab is active in malignant effusion.

  2006cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• Vascular endothelial growth factor in pleural effusions of different origin

  2005cited by this paper
• Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.

  2002cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer

  1999cited by this paper
• Vascular endothelial growth factor in pleural fluid.

  1999cited by this paper
• Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions

  1999cited by this paper
• Prognostic value of pleural effusion in patients with non-small cell lung cancer.

  1997cited by this paper

• Oncolytic viruses: a promising therapy for malignant pleural effusion and solid tumors

  2025cites this paper
• The Evolving Role of Chemotherapy in the Management of Pleural Malignancies: Current Evidence and Future Directions

  2025influential citation
• Phase II study of ramucirumab and docetaxel for previously platinum-treated patients with non-small cell lung cancer and malignant pleural effusion (PLEURAM study)

  2024cites this paper
• American Association of Bronchology and Interventional Pulmonology Essential Knowledge in Interventional Pulmonology Series: Selected Topics in Malignant Pleural Disease.

  2024cites this paper
• Successful Treatment of Refractory Malignant Pleural Effusion in a Heavily Pre-treated Lung Adenocarcinoma Patient with EGFR Mutation Using a Combination of Erlotinib and Ramucirumab

  2024cites this paper
• Malignant Pleural Effusions in the Era of Immunotherapy and Antiangiogenic Therapy

  2023cites this paper
• Utility of atezolizumab plus bevacizumab, carboplatin, and paclitaxel combination for the treatment of advanced non-squamous non-small cell lung cancer patients with malignant pleural effusion

  2023cites this paper
• Development and validation of the CAIL prognostic score in non‐small cell lung cancer patients with malignant pleural effusion

  2023cites this paper
• Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer

  2023cites this paper
• Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors

  2022cites this paper
• The role of angiogenesis in malignant pleural effusion: from basic research to clinical application.

  2022cites this paper
• Successful treatment of extensive-stage small cell lung cancer with concurrent pleural and pericardial effusions: Case report

  2022cites this paper
• Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab + Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer

  2022cites this paper
• Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab + Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer

  2022cites this paper
• Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study

  2022cites this paper
• Lenvatinib for poorly differentiated carcinoma of the anterior mediastinum

  2021cites this paper
• Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study

  2021cites this paper
• Novel therapies for malignant pleural effusion: Anti‑angiogenic therapy and immunotherapy (Review).

  2021influential citation
• Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion

  2021influential citation
• Malignant pleural effusion in lung cancer: focus on treatment—through a review of literature

  2020cites this paper
• Bevacizumab plus chemotherapy in nonsquamous non‐small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B

  2020cites this paper
• Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)

  2020cites this paper
• Prognostic factors of recurrence of malignant pleural effusion: what is the role of neoplasia progression?

  2020cites this paper
• Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy

  2020cites this paper
• Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study

  2019cites this paper
• 贝伐珠单抗治疗非小细胞肺癌所致恶性胸腔积液的研究进展

  2019cites this paper
• Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.

  2019cites this paper
• Cutaneous metastasis from lung adenocarcinoma presenting before discovery of the primary malignancy: a case report.

  2019cites this paper
• Phase II study of ramucirumab and docetaxel for previously treated non‐small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study

  2019cites this paper
• Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma‐induced malignant pleural effusion

  2018cites this paper
• Better efficacy of intrapleural infusion of bevacizumab with pemetrexed for malignant pleural effusion mediated from nonsquamous non-small cell lung cancer

  2018cites this paper
• ERS/EACTS statement on the management of malignant pleural effusions

  2018cites this paper
• ERS/EACTS statement on the management of malignant pleural effusions

  2018cites this paper
• Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers

  2018cites this paper
• The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer

  2018cites this paper
• Evaluation of Detection Methods and Values of Circulating Vascular Endothelial Growth Factor in Lung Cancer

  2018cites this paper
• Wet M1a non-small cell lung cancer: is it possible to predict recurrence of pleural effusion?

  2018cites this paper
• Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial

  2018cites this paper
• Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer

  2018cites this paper
• Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients

  2017cites this paper
• A Case of Lung Adenocarcinoma with Marked Improvement of Pulmonary Lymphangitic Carcinomatosis by Adding Bevacizumab to Cisplatin and Pemetrexed

  2017cites this paper
• Effectiveness of intraperitoneal or intrapleural administration of triamcinolone acetonide for the control of malignant ascites and pleural effusion (Kansai Clinical Oncology Group-G1102 study)

  2017cites this paper
• Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature

  2017cites this paper
• A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.

  2016cites this paper
• Greater efficacy of intracavitary infusion of bevacizumab compared to traditional local treatments for patients with malignant cavity serous effusion

  2016influential citation
• Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.

  2016cites this paper
• Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases

  2016cites this paper
• Dual Functional Peptide-Driven Nanoparticles for Highly Efficient Glioma-Targeting and Drug Codelivery.

  2016cites this paper
• A propensity score-matched comparison of the efficacies of OK-432 and talc slurry for pleurodesis for malignant pleural effusion induced by lung adenocarcinoma.

  2016cites this paper
• Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness.

  2016cites this paper
• VEGF : un biomarqueur potentiel dans la physiopathologie cardiovasculaire

  2015cites this paper
• Impact of itraconazole on the survival of heavily pre-treated patients with triple-negative breast cancer.

  2014cites this paper